Skip to main content

Advertisement

Table 1 Whole exome sequencing of patients-derived biopsies and xenografts

From: Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Sample Yield (Gbases) Reads (× 106) % ≥ Q30 bases (PF) Key mutations
Biopsy from patient CTC15035EML4–ALK 13.63 90.88 90.73 EML4ALK fusion (EML4 exon18–ALK exon 20)
Crizotinib-6 xenograft 27.77 185.10 91.38 EML4ALK fusion (EML4 exon18–ALK exon 20); ALK: E1210K (9%)
Biopsy from patient CTC15063EGFR L858R, T790M 14.72 98.15 90.94 EGFR: L858R (85.7%) and T790M (71.5%)
Xenograft from patient CTC15063EGFR L858R, T790M 25.09 167.24 90.04 EGFR: L858R (83.3%) and T790M (77.6%)
Osimertinib-3 xenograft 27.38 182.52 90.73 EGFR: L858R (53.6%) and T790M (41.7%); PIK3C2A: R86fs (11%); BRAF: G7V (11.5%)
  1. Gbases gigabases, M million, PF post filter, EML4ALK echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, EGFR epidermal growth factor receptor